Illumina, Inc. (NASDAQ:ILMN) Receives Average Recommendation of “Hold” from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have been given a consensus recommendation of “Hold” by the eighteen research firms that are presently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $129.6875.

ILMN has been the subject of a number of research reports. TD Cowen reiterated a “hold” rating on shares of Illumina in a report on Wednesday, January 7th. Robert W. Baird set a $137.00 target price on Illumina in a research note on Friday, February 6th. Piper Sandler decreased their price target on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research note on Monday, February 9th. Zacks Research downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 31st. Finally, Evercore set a $150.00 price objective on shares of Illumina in a research report on Friday, February 6th.

Insider Transactions at Illumina

In other Illumina news, SVP Patricia Leckman sold 2,370 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the sale, the senior vice president directly owned 16,321 shares of the company’s stock, valued at $1,896,173.78. The trade was a 12.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Illumina

Several hedge funds have recently modified their holdings of ILMN. Capital World Investors raised its holdings in Illumina by 0.6% during the fourth quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock worth $2,636,483,000 after acquiring an additional 124,323 shares in the last quarter. State Street Corp grew its stake in Illumina by 3.2% in the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock valued at $811,895,000 after purchasing an additional 190,324 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Illumina by 30.3% during the 4th quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after purchasing an additional 1,028,099 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Illumina by 1.9% during the 2nd quarter. Loomis Sayles & Co. L P now owns 4,225,529 shares of the life sciences company’s stock worth $403,158,000 after purchasing an additional 78,317 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Illumina by 4.8% during the 4th quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company’s stock worth $375,260,000 after purchasing an additional 130,139 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 1.8%

Shares of NASDAQ:ILMN opened at $124.33 on Friday. The firm has a market cap of $19.01 billion, a price-to-earnings ratio of 22.81, a PEG ratio of 2.42 and a beta of 1.45. Illumina has a 12 month low of $68.70 and a 12 month high of $155.53. The company’s fifty day simple moving average is $130.92 and its 200 day simple moving average is $120.62. The company has a quick ratio of 1.72, a current ratio of 2.08 and a debt-to-equity ratio of 0.55.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The firm had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same period in the prior year, the business earned $0.95 EPS. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. As a group, research analysts forecast that Illumina will post 4.51 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.